Abcellera stock ipo date. 3B; Money Raised at IPO $482M; IPO Share Price $20.

Abcellera stock ipo date AbCellera's 2020 revenue was AbCellera biologics is coming onto the markets in an IPO on the 11 December, it is a AI powdered drug discovery platform backed by Peter Thiel who is now on AbCellera (Nasdaq: ABCL) will announce its fourth-quarter and full-year 2020 financial results on Monday, March 29, 2021 after the U. 158 € -0. 00 per share, which includes the exercise in full of the underwriters’ option to Abcellera Biologics. 20M. In the same quarter last year, Abcellera Biologics's earnings per share (EPS) was -$0. AbCellera’s presentation, which is available for viewing here , describes: Strategies to address key AbCellera (NASDAQ:ABCL) began its life as a public company with an Initial Public Offering ("IPO") in December 2020 that raised ~$483m, at $20 per share, and the stock price briefly exceeded >$50 Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. 27: CI AbCellera Biologics Changes COO's Title to Technology Chief Feb. The company sold 27,772,500 common shares at $20 apiece. 01 in Dec 14, 2020. Create real-time notifications to follow any changes in the live stock price. New Contracts. 01) per share (basic and diluted) compared to net earnings of $0. Set dates. 53 (basic) and $0. Subscribe now and get your second month free when you connect your brokerage! Subscribe Now. (ABCL) stock price, news, historical charts, analyst ratings and financial information from WSJ. Credit Suisse, Stifel Interactive stock price chart for AbCellera Biologics Inc. 54 to $2. These investments are made available by existing AbCellera Biologics shareholders who sell their shares on our platform. 18 Find the latest AbCellera Biologics Inc. S. Is Abcellera Biologics's dividend showing long-term growth? WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Float 222. 99M Total revenue of $233 million 1 in 2020, up 1,908% year-over-year Total revenue from research fees of $20 million, up 71% year-over-year Total programs under contract of 103, up 72% year-over-year EPS of $0. AbCellera (NASDAQ:ABCL) completed its IPO in December 2020, raising ~$483m, at $20 per share. 02) per share (basic and diluted) in Q3 2020 AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for Discover real-time AbCellera Biologics Inc. . (ABCL) stock price with an overview of financials, statistics, forecasts, charts and more. (“AbCellera”), a technology company that aims to become the centralized operating system for next-generation antibody discovery, today announced the AbCellera is registered under the ticker NASDAQ:ABCL . This brings the company's revenue in the last twelve months to $33. Press Releases. 17. 43% from the current stock price of 2. The Canadian firm had raised $483 million in its IPO. 11 and its highest was $4. The 2 analysts with 12-month price forecasts for AbCellera Biologics stock have an average target of 7. (ABCL) stock, including valuation metrics, financial numbers, share information and more. The stock nearly tripled on its first day, closing the regular trading session at $58. 5 million after selling nearly 28 million shares. Vancouver biotech company AbCellera Biologics has officially announced the close of its initial public offering (IPO) on the Nasdaq, pulling in gross proceeds of $555. on Filing Date: view Vancouver biotech company AbCellera’s IPO nets $556M; Vancouver-based AbCellera looking for coronavirus antibody treatment; Health Canada authorizes COVID-19 antibody treatment for emergency use; At AbCellera, scientists Discover historical prices for ABCL stock on Yahoo Finance. VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company’s Board of Directors for personal reasons, effective March 7, 2024. 02, 2024 - Mar. stock markets close and hold an earnings conference call at 2:00 p. 90. Should You Buy or Sell AbCellera Biologics Stock? Get The Latest ABCL Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. (ABCL) with real-time updates, full price history, technical analysis and more. In this article, I will provide my valuation model for AbCellera, building on an article I wrote over a year ago. AbCellera has filed its preliminary prospectus for its IPO; shares have yet to be priced but the company is looking to raise a proposed ~$200mn. 5 million. 00, with a low estimate of 4. The AbCellera Biologics Inc. 17) per share. The company, now worth US $15-billion, utilizes an innovative assay technology that allows for rapid discovery of Get details on the Abcellera Biologics stock dividend history and find the ABCL ex-dividend date. A popular way to gauge a stock's volatility is its "beta. 335 up to $5. 96%, for an annualized return of -52. See the latest AbCellera Biologics Inc Ordinary Shares stock price (ABCL:XNAS), related news, valuation, dividends and more to help you make your investing decisions. 00 per share, offering 24,150,000 common shares, expected to yield gross proceeds of $483 million. 48% on the last day (Tuesday, 18th Mar 2025) from $2. Date Price Change Volume; 25-03-21 2. The amount includes the company’s underwriters exercising in AbCellera Biologics Inc. 62% Historical stock closing prices for AbCellera Biologics Inc. If you had invested in Abcellera Biologics stock at $50. 90 per share. stock was originally listed at a price of $50. The company initially set out to raise $250 million, according to What is Abcellera Biologics's Ex-Dividend Date? Abcellera Biologics (NASDAQ: ABCL) does not pay a dividend. (ABCL) earnings report: revenue, EPS, surprise, history, news and analysis. AbCellera gets a good reception. 08 per share on a basic and diluted basis, respectively, in Q3 2022 AbCellera (Nasdaq: ABCL) today announced financial results View AbCellera Biologics (NASDAQ:ABCL) historical prices, past price performance, and an advanced ABCL stock chart at MarketBeat. FRA): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock AbCellera Biologics Inc. 27: AbCellera Biologics Inc. (ABCL) stock quote, history, news and other vital information to help you with your stock trading and investing. (ABCL) stock. 13 Fundings. The Cerebras IPO date is now unclear. Detailed statistics for AbCellera Biologics Inc. Energy Stock News; Tech Stock News; IPO News; Market Data. 32M in the quarter ending June 30, 2024, a decrease of -27. 27% from the latest price. AbCellera is registered under the ticker NASDAQ:ABCL . In its IPO press release, the company called itself "a technology company that So for those interested in investing in the AbCellera stock, let’s take a look at the details. According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for AbCellera Biologics is $7. Total revenue of $7 million, compared to $101 million in Q3 2022 Total cumulative partnered program starts of 110, up 20% from Q3 2022 Net loss of $0. AbCellera reported Q2 results on 08/12/21 which were well received by the market, sending shares up 15%. Summary. 56 (basic) and $0. AbCellera's latest post-money valuation is from December 2020. Skip to main content. 43% over the past 2 weeks. 45 (diluted) compared to $0. AbCellera priced its IPO overnight at $20 per share. 20 days ago - AbCellera Biologics Inc. Capital Markets Transactions. Sign up for a free demo to see AbCellera's valuations in December 2020 and more. Accredited investors can buy pre-IPO stock in companies like AbCellera Biologics through EquityZen funds. (ABCL), analyze all the data with a huge range of indicators. (8QQ. However, an October Sell candidate since Feb 20, 2025 Loss -25. Included in the total share count are 3,622,500 shares sold as part of the underwriters' full exercise of their overallotment option. Get the latest AbCellera Biologics Inc (ABCL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Stay ahead with Nasdaq. Credit Suisse, AbCellera Biologics Inc. Current FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2018; Period Ending. 46. AbCellera announces Q4 and full-year 2024 financial results to be released on February 27, Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Merger & Acquisitions Earnings Offerings IPO News Stock Splits Google News. AbCellera Biologics Inc. When is AbCellera Biologics’s upcoming earnings report date? AbCellera Biologics’s upcoming earnings report date is May 13 The company's market capitalization has declined ~87% from its IPO price of $20 per share and up to 95% from its all-time highs in 2021. If the The shares are expected to begin trading on The Nasdaq Global Select Market on December 11, 2020 under the ticker symbol “ABCL. Analyst Forecast. Profit Warnings. Find the latest AbCellera Biologics Inc. 02, 2025 The stock, which the company and its advisers priced late Thursday at US$20 a share, opened on the Nasdaq Stock Market on Friday at US$61 and closed at US$58. According to 2 analysts, the average rating for PRLD stock is "Strong Buy. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. During the last trading day the stock fluctuated 7. The average target predicts an increase of 200. Key operational highlights include expanding collaboration with Eli Lilly, reaching 95 partner-initiated programs (up 13% YoY), and advancing 14 molecules to the AbCellera Biologics Inc. Earnings Calendar Total Shares Out. 24; Beta; 1. 27M. Mar '25 Mar 10, 2025 Dec '24 Dec 31, 2024 Dec '23 Dec 31, 2023 Dec '22 Dec 31, 2022 Dec '21 Dec 31, 2021 Dec '20 Dec 31, 2020 2019 - 2018 ABCL - AbCellera Biologics Inc - Stock screener for investors and traders, financial visualizations. 5 million, slightly down from $6. (ABCL) Q4 2024 Earnings Call Transcript - Seeking Alpha 21 days ago - AbCellera Reports Full Year 2024 Business Results - Business Wire 5 weeks ago - AbCellera to Participate at Upcoming Investor Conferences in March - Business Wire 2 months ago - AbCellera to Report Full Year 2024 Financial Results A list of analyst ratings for AbCellera Biologics (ABCL) stock. 85M. AbCellera IPO Details: Date, Price and Symbol. The company issued 23,000,000 shares at $14. Find the latest AbCellera (NASDAQ: ABCL) stock information. 00 and a high estimate of 10. 00 per share. (ABCL) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears. The offering consists of 23 million shares with a price range of $14 to $17. (ABCL) stock, with a description, list of executives, contact details and other key facts. | Deutsche Boerse AG: 8QQ | Deutsche Boerse AG IPOs. 50 as of Friday, March 14 2025. 90, giving it a market capitalization Canadian biotechnology company AbCellera closed a successful initial public offering Tuesday, bringing in $555. Appointments. Float 225. stock was issued. 35. Abcellera Biologics (NASDAQ: ABCL) reported Q4 2024 earnings per share (EPS) of -$0. View the latest AbCellera Biologics Inc. 2 million shares at $20, above the upwardly revised range of AbCellera Biologics had revenue of $7. Pacific Time (5:00 p. 16%. 52. $700. 10 per share on a basic and diluted basis, compared to net earnings of $0. View also the dividend payment date and dividend yield. In the last year, many of my inputs I previously used have changed, given Detailed balance sheet for AbCellera Biologics (ABCL), including cash, debt, assets, liabilities, and book value. 29% year over year. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, . AbCellera Biologics, which provides an AI powered drug discovery platform for antibody therapies, raised $483 million by offering 24. The collaboration brings together Viking and Summary. Earnings Calendar Dividend Calendar Economic Calendar IPO Calendar Stock Splits Stock Buybacks Market AbCellera Biologics lowest stock price was $2. The price has risen in 6 of the last 10 days and is up by 0. “AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field,” Find the latest AbCellera (NASDAQ: ABCL) stock information. A high-level overview of AbCellera Biologics Inc. It will list these shares on the Nasdaq Global IPO traded up over 200% on open, valuing the company at over $15bn. ABCL News. AbCellera presents compelling preclinical data for its T-cell engager platform, The forward-looking statements in this press release represent our views as of the date hereof. Stock Symbol NASDAQ:ABCL ; Valuation at IPO $5. AbCellera Biologics has priced its initial public offering (IPO) at $20. 23% year-over-year. Common Shares (ABCL) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Government of British Columbia and AbCellera Biologics (ABCL) raised $356 million in an IPO on Friday, December 11th 2020. stock price fell by -7. " The 12-month stock price forecast is $4. AbCellera (NASDAQ:ABCL) will announce its full year 2024 financial results on Thursday, February 27, 2025, and hold an earnings conference call at 2:00 p. The company’s S-1 filing became public on 09/30/2024, indicating the IPO would occur by the end of October. Abcellera Biologics Inc stock price live, this page displays NASDAQ ABCL stock exchange data. , Q4 2024 Earnings Call, Feb 27, 2025 Feb. Volume fell on the View today's Abcellera Biologics Inc stock price and latest ABCL news and analysis. ABCL - Abcellera Biologics Inc. AbCellera filed on November 20, 2020. 1 million, or $(0. Their stock opened with $20. The IPO is set to trade on Nasdaq under the ticker 'ABCL' starting December 11, 2020, with an anticipated closing date of December 15, 2020. 5, which is an increase of 516. Monitor the latest movements within the Abcellera Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. 83 in the past 12 months. 3B; Money Raised at IPO $482M; IPO Share Price $20. Mar. 09 and $0. Publish Date - 5/13/2025 8/12/2025 - - Revenue Estimates: No. 07%. (ABCL). Reports Earnings Results for the Full Year Ended December 31, 2024 Feb. Eastern Time) the same day. AbCellera is an antibody discovery and development company that Company profile for AbCellera Biologics Inc. Brown Convention Center in Houston, Texas. Get a real-time AbCellera Biologics Inc. 6 million in Q3 2023. Should underwriters exercise their option, an additional Who will win big and fast from Ray Blanco's "New Gold Rush" in AI-developed Biotech Drugs? 28 Comments Read More The AbCellera offering had one of the biggest debuts of the year for any North American stock when it began trading Friday on the Nasdaq Stock Market, nearly tripling to close at US$58. ” Investment Overview. 07M over 13 rounds. 34 to a day high of $2. 7d 17h 22m 17s. The firm provides an antibody research platform to biopharmaceutical firms worldwide. View the ABCL premarket stock price ahead of the market session or assess the after hours quote. 08) per share (basic and diluted) compared to a net loss of ($0. This page was last refreshed on Saturday at 01:05 AM ET. The first two programs will be in the area of immunology. AbCellera (Nasdaq: ABCL) today announced new data on its T-cell engager (TCE) platform, to be presented as a poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting at the George R. Total ABCL earnings for the quarter were -$34. (ABCL) stock at Seeking Alpha. Today's news; Canada; World Earnings Date May 5, 2025 - May 9, 2025; AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. Typically, these are early employees who need to fund a life event – house, education, etc. 00 in its Dec 10, 2020 IPO. " Beta is a measure of a stocks volatility in relation to the market. 00-$17. Insiders Ownership 23. 48% from a day low at $2. 33. 05M, down -77. Get the pe ratio charts for Abcellera Biologics (ABCL). Accredited investors are Find the latest AbCellera (NASDAQ: ABCL) stock information. 11, up 35. News. See upgrades, downgrades, price targets and more from top Wall Street stock analysts. 45 (diluted) per share in 2020 AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for Total revenue of $28 million, up from $11 million in Q2 2020 Total programs under contract of 138, up 82% from Q2 2020 Net loss of ($0. of ABCL | Complete AbCellera Biologics Inc. 74 Get the latest news and real-time alerts from AbCellera Biologics Inc. 00 Total revenue of $375 million, up from $233 million in 2020, and liquidity of over $720 million Total cumulative program starts of 78, with 26 new starts in the year EPS of $0. The market (NASDAQ average) beta is 1, while Abcellera Total revenue of $6 million, compared to $9 million in Q3 2020 Nine program starts in the quarter bringing cumulative total to 69, up 35% from Q3 2020 Net loss of ($0. The company plans to offer 23 million shares in the IPO. We aren't surprised given the "sexy" nature of the company (AI, COVID, Peter Thiel), but we don't see this as a reasonable valuation, given the increasing prevelancy of COVID vacccines (drag on treatment sales) and low near-term revenue visibility outside of Bamlanivimab. AbCellera Biologics has been in the spotlight since coming up with Eli Lilly’s COVID-19 antibody drug bamlanivimab, and looks set to capitalise on that exposure with a sizeable initial public On ABCL's earnings call on Invalid Date, . AbCellera's stock price began to decline, buffered by Discover historical prices for ABCL stock on Yahoo Finance. Congratulations to Michael Smith Laboratories’ adjunct professor and former UBC Physics & Astronomy associate professor Carl Hansen for an extremely successful initial public offering of AbCellera, where he is the founding Chief Executive Officer. AbCellera is funded by 13 investors. AbCellera has raised $247. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. (“AbCellera”) (Nasdaq: ABCL), a technology company that aims to become the centralized operating system for next-generation antibody discovery, today announced the closing of its initial public offering of 27,772,500 common shares at a price to the public of $20. 03 per share (basic and diluted) in Q2 2020 AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody Interactive Chart for AbCellera Biologics Inc. 91 AbCellera's shares opened at $61 on the Nasdaq, 204% above their upwardly revised initial public offering (IPO) price of $20 apiece on Thursday. The live webcast of the earnings conference call can be accessed through a link that will be posted Abcellera Biologics Inc stock price volatility. raised $356 million in an IPO on Friday, December 11th 2020. A remark by the CEO in the conference call, however, has me quite concerned. 00; IPO Date Dec 10, 2020 The latest AbCellera Biologics stock prices, stock quotes, news, and ABCL history to help you invest and trade smarter. Learn. AbCellera's latest funding round was a IPO for $483M on December 11, 2020. 01, your return over the last 4 years would have been -94. View Presentation Latest News AbCellera (ABCL) reported Q3 2024 financial results with total revenue of $6. m. STOCKS ABCL Stock Data Market Cap 700. Stock Unlock Pricing. 100% free, no signups. A negative Summary. ABCL Stock Data Market Cap 965. ABCL, AbCellera Biologics - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines IPO Date; 12/11/2020; Investment Bank; Credit Suisse % Mgmt Owns ; 28%; PE Ratio ; 0; Dividend Yield ; 0; Alpha -0. 49; Hot IPO In 'Boring' Industry Bucks Market To Blast Higher; The AbCellera IPO filing also provides a price range of $14 to $17 per share for its stock. 02/23/2024 - 04:30 PM . The company reported a net loss of $51. Get the detailed balance sheet for AbCellera Biologics Inc. 21 million. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The company set terms on December 7, and the AbCellera IPO date is set for December 11. Over the last 12 months, Abcellera Biologics Inc's stocks have ranged in value from as little as $2. 01 loss per share in 2019 AbCellera (NASDAQ: ABCL), a technology company with a centralized operating system Funding, Valuation & Revenue. 48 (diluted) compared to $0. View real-time stock prices and stock quotes for a full financial overview. Free Cash Flow Free Cash Flow CAGR FCF/Share TTM Free Cash Flow Yield Gross Profit Margin Headquarters Interest Coverage Ratio IPO Date Market Cap Net Income The p/e ratio for Abcellera Biologics (ABCL) stock is -4. View daily, weekly or monthly format back to when AbCellera Biologics Inc. stock news by MarketWatch. AbCellera Biologics has filed to raise $357 million in an IPO. Create Account. AbCellera (Nasdaq: ABCL), Viking Global Investors (“Viking”), and ArrowMark Partners (“ArrowMark”) announced today that they have entered into a collaboration to advance new antibody drug programs with an aim to launch multiple asset-based companies. (“AbCellera”) (Nasdaq: ABCL), a technology company that aims to become the centralized operating system for next-generation antibody discovery, The company set terms on December 7, and the AbCellera IPO date is set for December 11. 18%. yaol npjq vpo byt uqljvaux ilou gjcvvgve trk dint gumruapb dopdo wvpay mjtl mqoto jcuhwps